Crescendo Biologics hits second target in Takeda collaboration

16 August 2018

Imperial Innovations Group (AIM: IVO) portfolio company Crescendo Biologics says that it has achieved another technical milestone in its collaboration with a Japanese pharma major.

The development comes as part of the developer of targeted T-cell engagers’ global, strategic, multi-target collaboration and license agreement with Takeda Pharmaceutical (TYO: 4502) announced in October 2016, and provided for Crescendo to earn as much as $790 million in upfront and clinical development, regulatory and sales-based milestones

Under this agreement, UK-based Crescendo’s proprietary transgenic platform and engineering expertise is used to identify and configure Humabody-based therapeutics against certain targets selected by Takeda. Humabodies are a fraction of the size of antibodies and can be linked together in a “daisy chain” to fight tumors in more than one way.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK